Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To test the effect of a tailored lighting intervention controlled by the Readings At Desk (RAD) controller on sleep and mood in Alzheimer's disease participants.
Each participant will be enrolled for 22 weeks. Participants will be randomly assigned to receive either the active or control lighting condition. Each lighting condition will be 8 weeks in length. After a 4 week washout, each participant will crossover to the opposite condition. Assessments will be performed before and at the end of each lighting intervention.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active lighting intervention then Control lighting condition | Active Comparator | Each lighting condition will be 8 weeks in length. After a 4 week washout, each participant will crossover to the opposite condition. |
|
| Control lighting condition then Active light intervention | Active Comparator | Each lighting condition will be 8 weeks in length. After a 4 week washout, each participant will crossover to the opposite condition. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Active lighting intervention | Device | Lighting intervention designed to impact the circadian system |
|
| Measure | Description | Time Frame |
|---|---|---|
| Sleep disturbance using the Pittsburgh Sleep Quality Index | The Pittsburgh Sleep Quality Index (PSQI) is composed of 19 items that generate 7 component scores. The sum of the 7 component scores yields a single global score with a range of 0 to 21. A global score >5 is considered to indicate sleep disturbances. A lower global score indicates improvement in sleep disturbance. | up to 22 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Depression screening utilizing the Cornell Scale for Depression in Dementia (CSDD) | The CSDD is a a 19-item tool designed to rate symptoms of depression in patients with dementia. This tool evaluates the presence and extent of mood-related signs. Scores range from 0 to 38 with a higher score indicating higher depressive symptoms. | up to 22 weeks |
Not provided
Inclusion criteria:
Exclusion criteria:
- use of sleep medication
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mariana Figueiro, PhD | Mount Sinai Icahn School of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Light and Health Research Center | Menands | New York | 12204 | United States |
Since this data collection occurs in a population with Alzheimer's disease, participants are generally not interested in individual results.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jul 2, 2026 |
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| ID | Term |
|---|---|
| D003704 | Dementia |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Participants will randomly be assigned to initially receive the active or control lighting intervention
Not provided
Not provided
Not provided
| Control lighting intervention | Device | Lighting intervention designed to have no impact on the circadian system |
|
| Sleep efficiency measured by actigraphy | Sleep efficiency is calculated from the wrist worn actigraph by the software program as the percentage of the time in bed spent sleeping. The ratio of total sleep time (TST) to total time in bed (TIB) multiplied by 100 to yield a percentage. | up to 22 weeks |
| D024801 |
| Tauopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |